FI3395423T3 - Vuotaneen affiniteettipuhdistusligandin poistaminen - Google Patents

Vuotaneen affiniteettipuhdistusligandin poistaminen Download PDF

Info

Publication number
FI3395423T3
FI3395423T3 FIEP18168494.5T FI18168494T FI3395423T3 FI 3395423 T3 FI3395423 T3 FI 3395423T3 FI 18168494 T FI18168494 T FI 18168494T FI 3395423 T3 FI3395423 T3 FI 3395423T3
Authority
FI
Finland
Prior art keywords
protein
chromatography medium
anion exchange
recombinant protein
exchange matrix
Prior art date
Application number
FIEP18168494.5T
Other languages
English (en)
Finnish (fi)
Inventor
Samuel Ray Trejo
Robert Perry Brake
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50424772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3395423(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of FI3395423T3 publication Critical patent/FI3395423T3/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361Ion-exchange
    • B01D15/363Anion-exchange
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804Affinity chromatography
    • B01D15/3809Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/10Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FIEP18168494.5T 2013-03-14 2014-03-11 Vuotaneen affiniteettipuhdistusligandin poistaminen FI3395423T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361785038P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
FI3395423T3 true FI3395423T3 (fi) 2023-11-02

Family

ID=50424772

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18168494.5T FI3395423T3 (fi) 2013-03-14 2014-03-11 Vuotaneen affiniteettipuhdistusligandin poistaminen

Country Status (17)

Country Link
US (3) US20160024144A1 (cg-RX-API-DMAC7.html)
EP (3) EP4026596A1 (cg-RX-API-DMAC7.html)
JP (1) JP6457479B2 (cg-RX-API-DMAC7.html)
AU (1) AU2014240596B2 (cg-RX-API-DMAC7.html)
CA (1) CA2904411A1 (cg-RX-API-DMAC7.html)
CY (1) CY1120353T1 (cg-RX-API-DMAC7.html)
DK (2) DK3395423T3 (cg-RX-API-DMAC7.html)
ES (2) ES2964601T3 (cg-RX-API-DMAC7.html)
FI (1) FI3395423T3 (cg-RX-API-DMAC7.html)
HU (2) HUE038565T2 (cg-RX-API-DMAC7.html)
LT (2) LT2969099T (cg-RX-API-DMAC7.html)
MX (2) MX365501B (cg-RX-API-DMAC7.html)
PL (2) PL2969099T5 (cg-RX-API-DMAC7.html)
PT (2) PT2969099T (cg-RX-API-DMAC7.html)
SI (2) SI3395423T1 (cg-RX-API-DMAC7.html)
TR (1) TR201809050T4 (cg-RX-API-DMAC7.html)
WO (1) WO2014159441A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160024144A1 (en) 2013-03-14 2016-01-28 Amgen Inc. Removal of leaked affinity purification ligand
TWI596107B (zh) * 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
US10556942B2 (en) * 2014-06-13 2020-02-11 Lupin Limited Process for the purification of TNFR:Fc fusion protein
CN105214341B (zh) * 2015-09-17 2017-12-15 广州康盛生物科技有限公司 组合型吸附柱及其制备方法
US20200283472A1 (en) * 2016-03-29 2020-09-10 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
JP7065105B2 (ja) * 2017-02-09 2022-05-11 ブラッコ・スイス・ソシエテ・アノニム 可溶性psgl-1タンパク質変異体の精製のための方法
CN118047854B (zh) * 2024-02-26 2024-08-02 武汉鹰达生物科技有限公司 一种人载脂蛋白a-i的分离纯化方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
DE3811042A1 (de) 1988-03-31 1989-10-19 Merck Patent Gmbh Ionenaustauscher
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
DE4333821A1 (de) 1993-10-04 1995-04-06 Merck Patent Gmbh Ionenaustauscher
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
DE19501726A1 (de) 1995-01-20 1996-07-25 Merck Patent Gmbh Polymerisationsfähige Derivate von Polyamiden
US5763223A (en) 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
ATE204004T1 (de) 1996-06-21 2001-08-15 Merck Patent Gmbh Polymere sorbentien auf basis polymerisationsfähiger derivate von polyamiden
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6398962B1 (en) 1997-06-18 2002-06-04 Merck Kgaa Use of monolithic sorbents for preparative chromatographic separation
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
EP1463942B2 (en) 2001-12-21 2012-06-20 Immunex Corporation Methods for purifying protein
CN104610422A (zh) * 2005-03-11 2015-05-13 惠氏公司 弱分配层析的方法
TW200827445A (en) * 2006-11-08 2008-07-01 Wyeth Corp Rationally designed media for cell culture
BRPI1009447A2 (pt) * 2009-03-11 2016-03-01 Wyeth Llc métodos de purificação de proteínas imunofarmacêuticas modulares pequenas
EP2598515B1 (en) * 2010-07-30 2016-09-21 Pfizer Inc Tandem purification of proteins
EP2723759A4 (en) * 2011-06-24 2015-01-28 Reddys Lab Ltd Dr PURIFICATION OF CHIMERIC PROTEIN
DK2729482T3 (en) * 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
WO2013063702A1 (en) * 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
SG10201701224UA (en) * 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
US20160024144A1 (en) * 2013-03-14 2016-01-28 Amgen Inc. Removal of leaked affinity purification ligand

Also Published As

Publication number Publication date
US20220144886A1 (en) 2022-05-12
CA2904411A1 (en) 2014-10-02
EP2969099B1 (en) 2018-04-25
PL2969099T3 (pl) 2018-10-31
ES2674697T3 (es) 2018-07-03
HUE064450T2 (hu) 2024-03-28
MX365501B (es) 2019-06-05
AU2014240596B2 (en) 2018-09-27
US11192919B2 (en) 2021-12-07
EP4026596A1 (en) 2022-07-13
HUE038565T2 (hu) 2018-10-29
MX2019006568A (es) 2019-08-22
US11492372B2 (en) 2022-11-08
EP3395423A1 (en) 2018-10-31
EP2969099B2 (en) 2021-12-22
AU2014240596A1 (en) 2015-09-24
PT3395423T (pt) 2023-11-14
CY1120353T1 (el) 2019-07-10
DK2969099T3 (en) 2018-07-09
JP2016513643A (ja) 2016-05-16
PL3395423T3 (pl) 2024-03-18
TR201809050T4 (tr) 2018-07-23
EP2969099A1 (en) 2016-01-20
DK2969099T4 (da) 2022-03-14
MX391507B (es) 2025-03-21
SI2969099T2 (sl) 2022-04-29
HK1220159A1 (en) 2017-04-28
ES2964601T3 (es) 2024-04-08
JP6457479B2 (ja) 2019-01-23
MX2015011994A (es) 2015-12-01
DK3395423T3 (da) 2023-11-20
SI3395423T1 (sl) 2023-12-29
PT2969099T (pt) 2018-07-05
US20160024144A1 (en) 2016-01-28
SI2969099T1 (sl) 2018-09-28
ES2674697T5 (es) 2022-04-19
WO2014159441A1 (en) 2014-10-02
US20190085021A1 (en) 2019-03-21
PL2969099T5 (pl) 2022-06-13
LT3395423T (lt) 2023-12-11
LT2969099T (lt) 2018-09-10
EP3395423B1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
FI3395423T3 (fi) Vuotaneen affiniteettipuhdistusligandin poistaminen
JP2016513643A5 (cg-RX-API-DMAC7.html)
CY1116129T1 (el) Καθαρισμος αντισωματος με κατιονανταλλακτικη χρωματογραφια
JP2012018171A5 (cg-RX-API-DMAC7.html)
BRPI0611600B8 (pt) método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
CY1122221T1 (el) Μεθοδοι αφαιρεσης ρυπου χρησιμοποιωντας ιοντοανταλλακτικη μεμβρανικη χρωματογραφια μετατοπισης γηγενων πρωτεϊνων
AR074015A1 (es) Purificacion de proteinas acidas utilizando cromatografia de hidroxiapatita ceramica
MX395730B (es) Uso de lavados alcalinos durante la cromatografia para remover impurezas.
RU2012130151A (ru) Промывочный раствор и способ промывки для аффинной хроматографии
SE0400501D0 (sv) Antibody purification
RU2014111820A (ru) Способы элиминации вируса
EA201592192A1 (ru) Способ очистки моноклональных антител
JP2014500311A5 (cg-RX-API-DMAC7.html)
JP2016530533A5 (cg-RX-API-DMAC7.html)
JP2017521389A5 (cg-RX-API-DMAC7.html)
BR112014015101A2 (pt) cromatografia de membrana de troca iônica
WO2007075283A3 (en) Polishing steps used in multi-step protein purification processes
RU2017101727A (ru) Способы и реагенты для очистки белков
JP2018510867A5 (cg-RX-API-DMAC7.html)
ATE547521T1 (de) Verfahren zur reinigung von nukleinsäure
EP4371996A3 (en) Methods for purifying antibodies
JP2012503170A5 (cg-RX-API-DMAC7.html)
JP2014507368A5 (cg-RX-API-DMAC7.html)
WO2007081906A3 (en) Purification by column-chromatography using eluants containing organic solvents
Westra et al. Immobilised metal-ion affinity chromatography purification of histidine-tagged recombinant proteins: a wash step with a low concentration of EDTA